Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. (ACHV) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ACHV · as of Sep 30, 2025
Ownership Breakdown
72
Institutional Holders
▲ 4 vs Q2
$48.92M
Total Inst. Value
▼ $10.38M vs Q2
102.66M
Shares Outstanding
freeFloat 84.99%
15.54M
13F Shares Held
▼ 10.70M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ACHV largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
PROPEL BIO MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 3.79M | 10.92% | 10.92% | $11.93B | Nov 12, 2025 | ▼ 2.37M |
VANGUARD GROUP INC in vitro & in vivo diagnostic substances | 2.46M | 7.10% | 7.10% | $7.75B | Nov 7, 2025 | ▲ 311.9K |
SIMPLIFY ASSET MANAGEMENT INC. in vitro & in vivo diagnostic substances | 1.18M | 3.42% | 3.42% | $3.73B | Oct 20, 2025 | — held |
MARSHALL WACE, LLP in vitro & in vivo diagnostic substances | 774.9K | 2.23% | 2.23% | $2.44B | Nov 13, 2025 | NEW |
NANTAHALA CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 648.9K | 1.87% | 1.87% | $2.04B | Nov 14, 2025 | ▼ 250.0K |
GEODE CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 507.0K | 1.46% | 1.46% | $1.60B | Nov 12, 2025 | ▲ 144.8K |
PATHSTONE HOLDINGS, LLC in vitro & in vivo diagnostic substances | 502.0K | 1.45% | 1.45% | $1.58B | Nov 13, 2025 | NEW |
RAYMOND JAMES FINANCIAL INC in vitro & in vivo diagnostic substances | 456.4K | 1.32% | 1.32% | $1.44B | Nov 14, 2025 | ▲ 161.3K |
CLEARLINE CAPITAL LP in vitro & in vivo diagnostic substances | 451.2K | 1.30% | 1.30% | $1.42B | Nov 14, 2025 | ▼ 875.0K |
TWO SIGMA INVESTMENTS, LP in vitro & in vivo diagnostic substances | 439.1K | 1.27% | 1.27% | $1.38B | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+2.21M shares13
New Positions
first time holders10
Decreased
−11.54M shares0
Sold Out
fully exitedNet shares change (top 50)
9.33M
+2.21M / −11.54M
Net new holders
+25
13 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ACHV insider trading · insider activity
Source: SEC Form 4
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Waldman Reid Alexander director | May 29, 2026 | Award | 47,250 | $5.24 | $247.6K | 47.3K | Form 4 ↗ |
Farrow Jeffrey S director | May 29, 2026 | Award | 47,250 | $5.24 | $247.6K | 47.3K | Form 4 ↗ |
Martin Christopher Nathan director | May 11, 2026 | Award | 47,250 | $5.59 | $264.1K | 47.3K | Form 4 ↗ |
Goldberg Andrew D. CEO and President | Apr 18, 2026 | Award | 11,706,270 | — | — | 11.71M | Form 4 ↗ |
Goldberg Andrew D. CEO and President | Apr 18, 2026 | Award | 3,601,929 | $4.25 | $15.31M | 3.60M | Form 4 ↗ |
Goldberg Andrew D. CEO and President | Apr 18, 2026 | Award | 1,800,965 | — | — | 1.80M | Form 4 ↗ |
Rubinstein Mark Lawrence Chief Medical Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Oki Mark K Chief Financial Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Xinos Jaime Chief Commercial Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Donnelly Craig Chief Operations Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Achieve Life Sciences, Inc. (ACHV) is primarily owned by institutional investors, who hold approximately 15.1% of total shares outstanding. Company insiders own approximately 15.01%, while retail and public investors account for the remaining 69.85%.
The largest institutional shareholder of Achieve Life Sciences, Inc. is PROPEL BIO MANAGEMENT, LLC, holding approximately 3.79 million shares — equal to 10.92% of outstanding shares — as of September 30, 2025.
A total of 72 institutional investors currently hold ACHV stock, with a combined institutional value of approximately $48,921,838 as of the most recent 13F filing period.
Frequently asked questions
ACHV ownershipAchieve Life Sciences, Inc. (ACHV) is primarily owned by institutional investors, who hold approximately 15.1% of shares. The largest shareholder is PROPEL BIO MANAGEMENT, LLC with a 10.92% stake. Company insiders hold 15.01%. Data sourced from SEC Form 13F as of September 30, 2025.